Identification of cancer stem cell-related genes through single cells and machine learning for predicting prostate cancer prognosis and immunotherapy
Source check: Source checked. Not independent scientific confirmation.
Finding: Single-cell analysis and random-forest prioritization identified HSPE1; four external datasets and 60 prostate specimens support a specific prognostic marker result. This record is limited to the study result and does not establish independent replication or real-world benefit.
Technology: Random forest and single-cell clustering
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- The paper uses single-cell clustering and random forest to prioritize stem-cell genes, then tests a multigene diagnostic model in four separate datasets.
- Test and result
- Single-cell analysis and random-forest prioritization identified HSPE1; four external datasets and 60 prostate specimens support a specific prognostic marker result.
- Limitation / still unknown
- No prospective clinical benefit or broader external validity is established by the documented study.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1464698/full · https://europepmc.org/article/MED/39267762
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.